Clinical trial · Interventional
Methionine PET/CT Studies In Patients With Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to test the usefulness of imaging with radiolabeled methionine in the evaluation of children and young adults with tumor(s). Methionine is a naturally occurring essential amino acid. It is crucial for the formation of proteins. When labeled with carbon-11 (C-11), a radioactive isotope of the naturally occurring carbon-12, the distribution of methionine can be determined noninvasively using a PET (positron emission tomography) camera. C-11 methionine (MET) has been shown valuable in the monitoring of a large number of neoplasms. Since C-11 has a short half life (20 minutes), MET must be produced in a facility very close to its intended use. Thus, it is not widely available and is produced only at select institutions with access to a cyclotron and PET chemistry facility. With the new availability of short lived tracers produced by its PET chemistry unit, St. Jude Children's Research Hospital (St. Jude) is one of only a few facilities with the capabilities and interests to evaluate the utility of PET scanning in the detection of tumors, evaluation of response to therapy, and distinction of residual tumor from scar tissue in patients who have completed therapy. The investigators propose to examine the biodistribution of MET in patients with malignant solid neoplasms, with emphasis on central nervous system (CNS) tumors and sarcomas. This project introduces a new diagnostic test for the noninvasive evaluation of neoplasms in pediatric oncology. Although not the primary purpose of this proposal, the investigators anticipate that MET studies will provide useful clinical information for the management of patients with malignant neoplasms.
Conditions
Conditions (14)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Stem Glioma | Brain Stem Glioma | ONTOLOGY_EXACT | 0.90 |
| Brain Tumors and/or Solid Tumors Including | — | UNRESOLVED | — |
| Craniopharyngioma | Craniopharyngioma | ONTOLOGY_EXACT | 0.90 |
| Ependymoma | Ependymoma | ONTOLOGY_EXACT | 0.90 |
| Ewing Sarcoma | Ewing Sarcoma | ONTOLOGY_EXACT | 0.98 |
| High Grade CNS Tumors | — | UNRESOLVED | — |
| Hodgkin Lymphoma | Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Low Grade CNS Tumors | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Methionine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Participants
- description
- Participants who meet the eligibility criteria in the study will receive methionine.
- interventionNames
- Drug: Methionine
Primary outcomes (1)
- measure
- Success rate of methionine (MET) for visualizing tumors
- timeFrame
- Baseline
- description
- To estimate the success rate of methionine (MET) for visualizing tumors at the time of diagnosis. We hypothesize that at least 70% of tumors within each group studied will be successfully visualized.
Secondary outcomes (2)
- measure
- Association of methionine uptake with tumor grade
- timeFrame
- End of study (maximum of 3 years post methionine infusion and PET scan)
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * All participants under the care of St. Jude physicians with known or suspected neoplastic disease are eligible for participation. * Participants will have had, or are scheduled to have clinical imaging evaluations which may include FDG PET CT, or CT, or MRI within 4 weeks of entry. * No limit on age or gender. * Female participants of childbearing age must not be lactating due to theoretical potential harm to the infant from exposure to radiation. * Informed consent signed by participant, parent, or guardian according to the guidelines of the institutional review board. Exclusion Criteria: * More than 6 MET PET scans within the previous 12 months. * Inability or unwillingness of research participant, parent, or legal guardian/representative to give written informed consent. Inclusion Criteria for Open-Access * All participants under the care of St. Jude physicians with known or suspected neoplastic disease are eligible for participation. * No limit on age or gender * Female participants of childbearing age must not be lactating due to theoretical potential harm to the infant from exposure to radiation. * Informed consent signed by participant, parent, or guardian according to the guidelines of the institutional review board. Exclusion Criteria for Open-Access * More than 6 MET PET scans within the previous 12 months. * Inability or unwillingness of research participant, parent, or legal guardian/representative to give written informed consent.
References
Publications (0)
Data not yet available